Business Context and Reporting Period
This Form 8-K was filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on May 5, 2022. The report details the entry into a Material Definitive Agreement for a registered direct offering of common stock and pre-funded warrants.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered Direct Offering.
- Securities Issued: Up to 10,752,688 shares of Common Stock and pre-funded warrants to purchase up to 17,372,312 shares.
- Offering Price: $1.60 per share for Common Stock; $1.5999 per Pre-Funded Warrant.
- Estimated Gross Proceeds: Approximately $45 million (prior to deducting commissions and expenses).
- Expected Closing Date: May 9, 2022.
- Financial Position: The filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity figures.
Material Changes and Use of Proceeds
The primary material change is the capital raise intended to fund specific clinical and commercial activities. The Company intends to use net proceeds for:
- Supporting the Biologics License Application (BLA) submission for pegzilarginase and its potential U.S. commercialization for Arginase 1 Deficiency.
- Advancing the Phase 1/2 clinical trial for AGLE-177 (Homocystinuria) and preparing for a potential Phase 3 trial.
- Advancing AGLE-325 (Cystinuria) through IND-enabling activities.
- Funding continued research and development, manufacturing, working capital, and general corporate purposes.
Guidance, Risks, and Unusual Items
Management Commentary: The offering is structured to provide immediate capital for critical development milestones. The Pre-Funded Warrants are exercisable immediately but include a beneficial ownership limitation of 4.99% (increasable to 19.99% with 61 days' notice).
Risks and Contingencies: The closing of the offering is subject to customary closing conditions. The filing does not explicitly list new risk factors beyond standard offering contingencies.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received versus the estimated $45 million.
- Confirm the dilution impact of the 10.75 million shares and 17.37 million pre-funded warrants on existing shareholders.
- Review the specific terms of the Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants.
- Monitor the status of the pegzilarginase BLA submission and AGLE-177 Phase 1/2 trial progress as funded by this capital.